Aidan Hollis
Aidan Hollis
Professor of Economics, University of Calgary
Verified email at ucalgary.ca - Homepage
Title
Cited by
Cited by
Year
Microcredit: What can we learn from the past?
A Hollis, A Sweetman
World Development 26 (10), 1875-1891, 1998
2781998
Co-authorship and the output of academic economists
A Hollis
Labour economics 8 (4), 503-530, 2001
1932001
The Health Impact Fund: Making New Medicines Accessible for All: a Report of Incentives for Global Health
A Hollis, TWM Pogge, Incentives for Global Health
Incentives for Global Health, 2008
1822008
Preserving antibiotics, rationally
A Hollis, Z Ahmed
New England Journal of Medicine 369 (26), 2474-2476, 2013
1392013
An economic justification for open access to essential medicine patents in developing countries
S Flynn, A Hollis, M Palmedo
The Journal of Law, Medicine & Ethics 37 (2), 184-208, 2009
1252009
The importance of being first: evidence from Canadian generic pharmaceuticals
A Hollis
Health Economics 11 (8), 723-734, 2002
1092002
A contractual approach to the gray market
NT Gallini, A Hollis
International Review of Law and Economics 19 (1), 1-21, 1999
971999
The large-scale integration of wind generation: Impacts on price, reliability and dispatchable conventional suppliers
J MacCormack, A Hollis, H Zareipour, W Rosehart
Energy policy 38 (7), 3837-3846, 2010
942010
The life-cycle of a microfinance institution: The Irish loan funds
A Hollis, A Sweetman
Journal of Economic Behavior & Organization 46 (3), 291-311, 2001
882001
An efficient reward system for pharmaceutical innovation
A Hollis
Retrieved Dec 9, 2004
822004
The anti-competitive effects of brand-controlled" pseudo-generics" in the Canadian pharmaceutical market
A Hollis
Canadian Public Policy/Analyse de Politiques, 21-32, 2003
822003
The Health Impact Fund: incentives for improving access to medicines
A Banerjee, A Hollis, T Pogge
Lancet (London, England) 12 (9709), 2010
752010
Microcredit in prefamine Ireland
A Hollis, A Sweetman
Explorations in Economic History 35 (4), 347-380, 1998
701998
How do brands’“own generics” affect pharmaceutical prices?
A Hollis
Review of Industrial Organization 27 (4), 329-350, 2005
502005
Microfinance and famine: the Irish loan funds during the great famine
A Hollis, A Sweetman
World Development 32 (9), 1509-1523, 2004
492004
Extended warranties, adverse selection, and aftermarkets
A Hollis
Journal of Risk and Insurance, 321-343, 1999
481999
Me-too drugs: is there a problem
A Hollis
WHO report, 2004
382004
The Health Impact Fund: boosting pharmaceutical innovation without obstructing free access
T Pogge
Cambridge Quarterly of Healthcare Ethics 18 (1), 78-86, 2009
36*2009
The health impact fund: a useful supplement to the patent system?
A Hollis
Public Health Ethics 1 (2), 124-133, 2008
362008
New approaches to rewarding pharmaceutical innovation
P Grootendorst, A Hollis, DK Levine, T Pogge, AM Edwards
Canadian Medical Association Journal, 2010
342010
The system can't perform the operation now. Try again later.
Articles 1–20